Ametop - Friend and Foe A Prospective Study of the Incidence of Adverse Reactions With Ametop
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Ametop was introduced into the formulary as it was deemed more efficacious for intravenous
cannulation compared to EMLA. However, the incidences of adverse reactions seemed to be
higher compared to other studies. This lead to a prospective observational study to look at
the incidence and severity of skin reactions following routine clinical application of
Ametop.